Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior

Journal of Clinical Psychiatry

Volumn 65, Issue 5, 2004, Pages 679-685

  Glick, Ira D ^a   Zaninelli, Rocco ^b   Hsu, Chuanchieh ^b   Young, Frederick K ^b   Weiss, Lilia ^b   Gunay, Ibrahim ^b   Kumar, Vinod ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUICIDE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE; TREATMENT OUTCOME;

EID: 2942737059     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0513     Document Type: Article

References (11)

1. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-59 (Pubitemid 36043847)
2. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14:33-40 (Pubitemid 30700515)
3. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry Suppl 1993;22:66-78 (Pubitemid 23355892)
4. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41-48 (Pubitemid 36192948)
5. Williams CL, Johnstone BM, Kesterson JG, et al. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37(suppl 4):AS81-AS86
6. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91 (Pubitemid 36070868)
7. Bezchlibnyk-Butler KZ, Jeffries JJ, eds. Clinical Handbook of Psychotropic Drugs. 12th ed. Seattle, Wash: Hogrefe & Huber; 2002:1-276
8. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Index With Defined Daily Doses (DDDs). Oslo, Norway: Norwegian Institute of Public Health; 2002
9. Couvee JE, Timmermans MA, Zitman FG, for the Dutch Chronic Benzodiazepine Working Group. The long-term outcome of a benzodiazepine discontinuation programme in depressed outpatients. J Affect Disord 2002;70:133-141
10. Brotman AW, McCormick S III. A role for high-dose antipsychotics. J Clin Psychiatry 1990;51:164-166 (Pubitemid 20129739)
11. Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001;9:346-360 (Pubitemid 33015123)